The stock of Haleon plc ADR (NYSE:HLN) last traded at $8.12, down -0.85% from the previous session.
Data from the available sources indicates that Haleon plc ADR (NYSE:HLN) is covered by 16 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.23 and a low of $7.30, we find $8.97. Given the previous closing price of $8.19, this indicates a potential upside of 9.52 percent. HLN stock price is now -1.67% away from the 50-day moving average and -2.46% away from the 200-day moving average. The market capitalization of the company currently stands at $37.49B.
In total, 6 analysts have assigned it a hold rating, and 7 have given it a buy rating. Brokers who have rated the stock have averaged $8.84 as their price target over the next twelve months.
With the price target of $9, Morgan Stanley recently initiated with Overweight rating for Haleon plc ADR (NYSE: HLN).
A total of 0.00% of the company’s stock is owned by insiders.
With an opening price of $8.22 on Wednesday morning, Haleon plc ADR (NYSE: HLN) set off the trading day. During the past 12 months, Haleon plc ADR has had a low of $7.07 and a high of $9.05. As of last week, the company has a debt-to-equity ratio of 0.60, a current ratio of 0.84, and a quick ratio of 0.54. The fifty day moving average price for HLN is $8.26 and a two-hundred day moving average price translates $8.32 for the stock.
The latest earnings results from Haleon plc ADR (NYSE: HLN) was released for Sep, 2023. For the current quarter, analysts expect HLN to generate $3.58B in revenue.
Haleon plc ADR(HLN) Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom.
